GB Sciences 

GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.